Pharmaceutical topical compositions
AssigneeFerrer Internacional, S.A.
InventorsCristina TARRAGÓ, Benjamin SANTOS, Manuel RAGA, Antonio GUGLIETTA
Life of this patent
Estimating the term…
Abstract
The invention provides pharmaceutical stable semisolid topical compositions comprising between 0.2 to 5% of a des-fluoroquinolone compound, and a suitable carrier to manufacture an ointment or a cream.
Claims6
A method of treatment or prevention of sexually transmitted diseases and genital tract infections comprising administering a stable topical cream composition to a subject in need thereof, said stable composition comprising:
- a) 0.2-5% of ozenoxacin, and
- b) a suitable carrier comprising:
- b.1) 15-25% of one or more emulsifiers selected from the group consisting of ethylene glycol monostearate, sorbitan tristearate, a mixture of PEG6 stearate, glycol stearate and PEG32 stearate, and hydrogenated lecithin, and mixtures thereof;
- b.2) 10-20% of one or more surfactants selected from the group consisting of sorbitan oleate monoolein/propylene glycol, C8C10 fatty acid mono- and diglycerides from coconut oil, soy lecithin, egg phosphatides, citric acid esters of monoglycerides, lactic acid esters of monoglycerides, diacetyl tartaric acid esters of monoglycerides, succinic acid esters of monoglycerides, sucrose fatty acid esters, polyglycolyzed glycerides of oleic acids, polyglycolyzed glycerides of linoleic acid, polyglycerol esters of fatty acids, and polyglyceryl esters of mixed fatty acids, and mixtures thereof;
- b.3) 5-15% of an oil component which is the Guerbet alcohol 2-octyl dodecanol;
- b.4) 1-10% of one or more low melting point waxes selected from the group consisting of fatty alcohols having 8 to 30 carbon atoms and mixtures thereof;
- b.5) water;
- b.6) 10-20% of one or more water dispersible components selected from the group consisting of polyethylene glycol 400, hexylene glycol, propylene glycol, polypropylene glycol-10 methylglucose ether, ethoxydiglycol, polyethylene glycol-6 caprylic/capric glyceride, ethylene glycol monobutyl ether, polyethylene glycol-8 caprylic/capric glycerides, 3-methoxy-3-methyl-1-butanol, dimethyl isosorbide, and mixtures thereof;
- and
- b.7) 0.01-1% of one or more non-formaldehyde-donating preservatives;
- wherein the amount of component b.5 is an amount to complete 100 percent by weight and all percentages being weight percent and based on the total weight of the composition.
A method of eradication of nasopharynx infections in asymptomatic nasal carriers comprising administering a stable topical cream composition to a subject in need thereof, said stable composition comprising:
- a) 0.2-5% of ozenoxacin, and
- b) a suitable carrier comprising:
- b.1) 15-25% of one or more emulsifiers selected from the group consisting of ethylene glycol monostearate, sorbitan tristearate, a mixture of PEG6 stearate, glycol stearate and PEG32 stearate, and hydrogenated lecithin, and mixtures thereof;
- b.2) 10-20% of one or more surfactants selected from the group consisting of sorbitan oleate monoolein/propylene glycol, C8C10 fatty acid mono- and diglycerides from coconut oil, soy lecithin, egg phosphatides, citric acid esters of monoglycerides, lactic acid esters of monoglycerides, diacetyl tartaric acid esters of monoglycerides, succinic acid esters of monoglycerides, sucrose fatty acid esters, polyglycolyzed glycerides of oleic acids, polyglycolyzed glycerides of linoleic acid, polyglycerol esters of fatty acids, and polyglyceryl esters of mixed fatty acids, and mixtures thereof;
- b.3) 5-15% of an oil component which is the Guerbet alcohol 2-octyl dodecanol;
- b.4) 1-10% of one or more low melting point waxes selected from the group consisting of fatty alcohols having 8 to 30 carbon atoms and mixtures thereof;
- b.5) water;
- b.6) 10-20% of one or more water dispersible components selected from the group consisting of polyethylene glycol 400, hexylene glycol, propylene glycol, polypropylene glycol-10 methylglucose ether, ethoxydiglycol, polyethylene glycol-6 caprylic/capric glyceride, ethylene glycol monobutyl ether, polyethylene glycol-8 caprylic/capric glycerides, 3-methoxy-3-methyl-1-butanol, dimethyl isosorbide, and mixtures thereof;
- and
- b.7) 0.01-1% of one or more non-formaldehyde-donating preservatives;
- wherein the amount of component b.5 is an amount to complete 100 percent by weight and all percentages being weight percent and based on the total weight of the composition.
A stable topical ointment composition comprising:
- a) 0.2-5% by weight (based on the total weight of the composition) of ozenoxacin, and
- b) a suitable carrier selected from the group consisting of white wax, white soft paraffin, and mixtures thereof,
- wherein the stable topical ointment composition is suitable for use in the treatment of sexually transmitted diseases and genital tract infections.
A stable topical ointment composition comprising:
- a) 0.2-5% by weight (based on the total weight of the composition) of ozenoxacin, and
- b) a suitable carrier selected from the group consisting of white wax, white soft paraffin, and mixtures thereof,
- wherein the stable topical ointment composition is suitable for use in the eradication of nasopharynx infections in asymptomatic nasal carriers.
A method for the treatment or prevention of sexually transmitted diseases and genital tract infections comprising administering a stable topical ointment composition to a subject in need thereof,
- wherein the stable topical ointment composition comprises:
- a) 0.2-5% by weight (based on the total weight of the composition) of ozenoxacin, and
- b) a suitable carrier selected from the group consisting of white wax, white soft paraffin, and mixtures thereof.
A method for eradication of nasopharynx infections in asymptomatic nasal carriers comprising administering a stable topical ointment composition to a subject in need thereof,
- wherein the stable topical ointment composition comprises:
- a) 0.2-5% by weight (based on the total weight of the composition) of ozenoxacin, and
- b) a suitable carrier selected from the group consisting of white wax, white soft paraffin, and mixtures thereof.
Dependencies are inferred from the claim text.